MedTrace Logo

Cabozantinib and Nivolumab for Carcinoid Tumors

NCT04197310 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-01-31

Study results available
· View outcomes & findings →

Summary

This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors.

\- Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.

Conditions

Interventions

DRUG

Nivolumab

240mg, intravenously, Day 1 and 15 of a 28 day cycle

DRUG

Cabozantinib

40mg, orally, Daily for a 28 day cycle

Sponsors & Collaborators

Principal Investigators

  • Kimberly Perez, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-26
Primary Completion
2023-12-27
Completion
2024-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04197310 on ClinicalTrials.gov